Joanna Y Yang

发表

Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens.

G. Richard, C. P. Mathew, J. Kirstein, 2002, Urology.

A Randomized, Double-blind Clinical Trial Comparing Cefepime Plus Metronidazole With Imipenem-Cilastatin in the Treatment of Complicated Intra-abdominal Infections

P. Barie, J. Solomkin, E. Dellinger, 1997 .

Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis

William M. Lee, E. Schiff, Z. Goodman, 2008, The American Journal of Gastroenterology.

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

C. Mazzucco, R. Colonno, A. Walsh, 2006, Antimicrobial Agents and Chemotherapy.

CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

A. Lok, R. Gish, R. Colonno, 2007 .

Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

Ronald E. Rose, R. Colonno, R. Rose, 2009, Hepatology.

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.

G. Carosi, Ting Chang, D. Shouval, 2009, Journal of hepatology.

Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance

R. Colonno, R. Rose, D. Tenney, 2008 .

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

A. Lok, R. Gish, Shou-Dong Lee, 2007, Gastroenterology.

Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901

E. Schiff, M. Sherman, Shou-Dong Lee, 2007 .

Hepatitis B Surface Antigen Loss in Antiviral-treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-naive Patients Treated with Entecavir (ETV) or lamivudine (LVD)

R. Gish, Ting Chang, F. Poordad, 2006 .

Randomized, Investigator-Blinded, Multicenter Study of Gatifloxacin Versus Amoxicillin/Clavulanate Treatment of Recurrent and Nonresponsive Otitis Media in Children

R. Echols, P. Pierce, K. Hamed, 2005, The Pediatric infectious disease journal.

Single-Dose Gatifloxacin Compared With Ofloxacin for the Treatment of Uncomplicated Gonorrhea: A Randomized, Double-Blind, Multicenter Trial

E. Hook, P. Leone, T. Mroczkowski, 2001, Sexually transmitted diseases.

A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.

T. Marbury, C. Cox, Joanna Y Yang, 2002, Clinical therapeutics.

Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patien

C. Bumroongkit, R. Badaró, Joanna Y Yang, 2003, Clinical therapeutics.

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B *

R. D. de Man, F. Poordad, Joanna Y Yang, 2010, Journal of viral hepatitis.

ENTECAVIR MAINTAINED VIROLOGIC SUPPRESSION THROUGH 3 YEARS OF TREATMENT IN ANTIVIRALNAı‥VE HBEAG PATIENTS (ETV 022/901)

Y. Chao, Ting Chang, R. Hindes, 2006 .

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.

G. Carosi, Ting Chang, D. Shouval, 2009, Journal of hepatology.